Clinical Trial Update: AVONEX® Combination Trial - "ACT" [Phase 4]

View source ↗

Summary

Completed Phase 4 AVONEX combination trial (ACT) in relapsing-remitting multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Avonex (Interferon beta-1a)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Status: COMPLETED